On February 14, 2012, KEI filed an affidavit in an India compulsory licensing case involving Bayer patents on cancer drug Sorafenib (Nexavar). The price for Nexavar in India is $47 per 200 milligram tablet. At a daily dose of 4 tablets, this comes to $5,637 per month, or more than $68 thousand per year. The per capita income in India was $1,330 in 2010.
Initial FDA approval
Date of FDA NDA application 21-923: Signed July 6, 2005. Received by FDA on July 8, 2005.
Date on FDA approval: December 20, 2005. Continue Reading →
Sangeeta Shashikant from TWN recently collected and published several NGO statements on the Africa IP Summit, in the TWO Info Service on Intellectual Property Issues (Feb12/03), which included a link also to a letter to WIPO signed by more than 100 NGOs. Continue Reading →
On February 8, 2012, seven public health organisations submitted a letter to Rep. Darrell Issa (R-CA), Chairman of the Committee on Oversight and Government Reform and the other thirty-nine members of this committee opposing H.R. 3699, the “Research Works Act.” This bill, originally introduced on December 16, 2011 by Rep. Issa and Rep. Maloney (D-NY) would prohibit federal agencies from conditioning its federal grants on recipients making its published research results available to the public. Continue Reading →
The United States Department of Commerce’s Commercial Law Development Program (CLDP) is the lead agency of a concerted effort involving the governments of France, Japan, South Africa and the United States, alongside the World Intellectual Property Organization (WIPO), Organisation Africaine de la Propriété Intellectuelle (OAPI), and the African Regional Intellectual Property Organization (ARIPO) to organize the inaugural “Africa Intellectual Property Forum: Intellectual Property, Regional Integration and Economic Gr Continue Reading →
On January 26, 2012, KEI sent a letter to Senator Patrick Leahy (D-VT), Chairman of the Judiciary Committee, calling for greater transparency in the Trans-Pacific Partnership Agreement (TPPA). The letter highlights the fact that the general public is kept in the dark regarding negotiating positions and the actual text while “cleared advisers” and corporate lobbyists have unequal access to information. It calls for Senator Leahy to urge the Obama Administration to release the negotiating text in order to allow full and effective public participation in our democratic society.
On December 16, 2011, H.R. 3699, “the Research Works Act”, was introduced by Rep. Darrell Issa (R-CA), Chairman of the Committee on Oversight and Government Reform, and Committee member Rep. Carolyn Maloney (D-NY). This is how the Association of American Publishers describes the bill:
On Wednesday, December 14, 2011 the Subcommittee on Trade of the Committee on Ways and Means held a hearing on the Trans-Pacific Partnership Agreement (TPPA). Oral testimony was accepted only from invited witnesses. These witnesses included: Ambassador Demetrios Marantis (Deputy U.S. Trade Representative), Devry S. Boughner (Director, Intenrational Business Relations on behalf of Cargill Inc. and U.S. Business Coalition for TPP), Angela Marshall Hofmann (Vice President for Global Integrated Sourcing on Trade, Wal-Mart Stores), and Michael Wessel (President of The Wessel Group).
On Wednesday, 7 December 2011, the United States of America tabled a proposal on patents and health which was distributed at 6 PM by the WIPO Secretariat after much of the substantive dicussions
Standing Committee on the Law of Patents
Seventeenth Session
Geneva, December 5 to 9, 2011
PATENTS AND HEALTH: PROPOSAL BY THE DELEGATION OF THE UNITED STATES OF AMERICA
The United States, on behalf of Group B (which includes Western European countries, Norway, the United States, Switzerland, Japan, Canada, New Zealand, Australia, Turkey, Israel and the Holy See) presented the following statement opposing the adoption of the African Group/Development Agenda Group on patents and health (in its current forum). In its individual intervention, the Holy See supported the African Group/Development Agenda Group proposal.
